10210 Campus Point Dr #150
5 articles about Rejuvenate Bio
More than $5 billion poured into the longevity space in 2022, and experts say the science is now primed to make a real difference in extending human healthspan.
Rejuvenate Bio Announces Data for Gene Therapy RJB-01 in Mitral Valve Disease at 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Rejuvenate Bio, announced new data for its gene therapy RJB-01 from a pilot study in canines with myxomatous mitral valve disease, at the 26th Annual Meeting of the American Society of Gene and Cell Therapy, held May 16-20, 2023, in Los Angeles, California.
Rejuvenate Bio Announces New Preclinical Research Evaluating Cellular Reprogramming for Age Reversal
Rejuvenate Bio, today announced new preclinical research published to the preprint server bioRxiv, that evaluates how partial reprogramming could be a potential treatment in the elderly to reverse age-associated diseases and potentially extend human lifespan.
Rejuvenate Bio Appoints Deborah Ascheim, M.D., as Chief Medical Officer
Rejuvenate Bio, today announced the appointment of Deborah Ascheim, M.D., as Chief Medical Officer.
Rejuvenate Bio Announces Expansion of Scientific Advisory Board
Rejuvenate Bio today announced the appointments of Hugh Calkins, M.D., Stephen Chelko, Ph.D., and Dr. Elif Oral, M.D., to its Scientific Advisory Board (SAB).